Brief: IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

IN8bio

16/12/2021 12:15

Dec 16 (Reuters) - IN8BIO, Inc.  INAB.O :
    * IN8BIO PROVIDES UPDATE FROM THE ONGOING PHASE 1 CLINICAL
TRIAL
OF ITS ALLOGENEIC GAMMA-DELTA T CELL THERAPY IN LEUKEMIA
PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT
    * IN8BIO, INC. - OF 3 PATIENTS THAT WERE DOSED WITH INB-100,
ALL
HAVE ACHIEVED AND REMAIN IN REMISSION TO DATE
    * IN8BIO, INC. - INB-100 CONTINUES TO DEMONSTRATE A
MANAGEABLE
SAFETY PROFILE TO-DATE

Source text for Eikon:  ID:nGNX8WDK4F 
Further company coverage:  INAB.O 

 ((Reuters.Briefs@thomsonreuters.com;;))